| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1992PNAS...8912180K |
| P356 | DOI | 10.1073/PNAS.89.24.12180 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC50722 |
| https://europepmc.org/articles/PMC50722?pdf=render | ||
| P932 | PMC publication ID | 50722 |
| P698 | PubMed publication ID | 1334560 |
| P5875 | ResearchGate publication ID | 21820270 |
| P2093 | author name string | D. R. Lowy | |
| J. T. Schiller | |||
| N. Cheng | |||
| F. Booy | |||
| R. Kirnbauer | |||
| P2860 | cites work | Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction | Q30447715 |
| Self-assembly of purified polyomavirus capsid protein VP1. | Q34162517 | ||
| Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation | Q34236875 | ||
| Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. | Q34505761 | ||
| Recent Progress in Defining the Epidemiology of Human Papillomavirus Infection and Cervical Neoplasia | Q35225570 | ||
| Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11 | Q36793675 | ||
| Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus | Q37259469 | ||
| Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions | Q37519329 | ||
| Proteins present in bovine papillomavirus particles | Q40141182 | ||
| Evidence of prevalent genital-type human papillomavirus infections in adults and children | Q41729431 | ||
| Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. | Q41734503 | ||
| Generation of recombinant baculovirus via liposome-mediated transfection | Q42071909 | ||
| The primary structure and genetic organization of the bovine papillomavirus type 1 genome | Q42665433 | ||
| Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF | Q42818510 | ||
| Identification of L2 open reading frame gene products of bovine papillomavirus type 1 using monoclonal antibodies | Q43693570 | ||
| Bovine serological response to a recombinant BPV-1 major capsid protein vaccine | Q43880669 | ||
| Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins | Q44234238 | ||
| Inside polyomavirus at 25-A resolution | Q44363789 | ||
| Topographical and conformational epitopes of bovine papillomavirus type 1 defined by monoclonal antibodies | Q44509171 | ||
| Synthesis and assembly of hepatitis B virus surface antigen particles in yeast | Q45793098 | ||
| A quantitative in vitro focus assay for bovine papilloma virus | Q45803536 | ||
| Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission | Q45839365 | ||
| Structure of simian virus 40 at 3.8-A resolution | Q45861692 | ||
| Human papillomavirus type 16 DNA sequence | Q48376786 | ||
| Monoclonal antibodies to genus- and type-specific papillomavirus structural antigens. | Q52489682 | ||
| Viruses in human cancers | Q56486194 | ||
| Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus | Q56797784 | ||
| The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes | Q67686616 | ||
| Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts | Q67698418 | ||
| Immunization against bovine papillomavirus infection | Q70142089 | ||
| A COMPARATIVE STUDY OF POLYOMA AND PAPILLOMA VIRUSES | Q76580918 | ||
| Further observations on immunity to bovine cutaneous papillomatosis | Q78850575 | ||
| Baculovirus vectors for multiple gene expression and for occluded virus production | Q95816342 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| self-assembly | Q910150 | ||
| capsid proteins | Q24779924 | ||
| P304 | page(s) | 12180-12184 | |
| P577 | publication date | 1992-12-01 | |
| 1992-12-15 | |||
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | |
| P478 | volume | 89 |
| Q49687633 | 9-Valent human papillomavirus vaccine: a review of the clinical development program |
| Q40049715 | A Prize for Cancer Prevention |
| Q45508177 | A Virus-based Vaccine May Prevent Cervical Cancer |
| Q35196119 | A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types |
| Q38885776 | A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice |
| Q36673310 | A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response |
| Q36448778 | A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5 |
| Q35009965 | A major role for the minor capsid protein of human papillomavirus type 16 in immune escape |
| Q39879423 | A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope |
| Q34593100 | A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection |
| Q28741364 | A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2 |
| Q37604412 | A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. |
| Q39285032 | A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers |
| Q35154570 | A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. |
| Q37219730 | A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. |
| Q36259403 | A review of clinical trials of human papillomavirus prophylactic vaccines |
| Q50315906 | A vaccine to prevent cervical cancer: academic and industrial collaboration and a Lasker award. |
| Q37604389 | A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. |
| Q59329445 | Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus |
| Q37830705 | Advances in human papilloma virus vaccines: a patent review |
| Q47951363 | Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. |
| Q42159117 | An effective DNA priming-protein boosting approach for the cervical cancer vaccination. |
| Q43096878 | Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity |
| Q37251390 | Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles |
| Q43957819 | Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles |
| Q57288656 | Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis |
| Q36673336 | Arrangement of L2 within the papillomavirus capsid |
| Q36632216 | Assembly of herpes simplex virus (HSV) intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV capsid proteins |
| Q35700066 | Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. |
| Q35915034 | Assessing parallel gene histories in viral genomes |
| Q35860748 | Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition |
| Q50542374 | Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. |
| Q27316846 | Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach |
| Q40210151 | Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity |
| Q35839345 | Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells |
| Q38172045 | Bioengineering virus-like particles as vaccines |
| Q38198822 | Bovine Papillomavirus: New Insights into an Old Disease |
| Q37219752 | Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. |
| Q34064413 | Branched-linear and agglomerate protein polymers as vaccine platforms |
| Q42040582 | C-terminal domain of hepatitis C virus core protein is essential for secretion |
| Q34069656 | CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles |
| Q33640368 | CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles |
| Q40642196 | Carboxy-fluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. |
| Q34743921 | Cell surface-binding motifs of L2 that facilitate papillomavirus infection |
| Q45407070 | Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer |
| Q37307576 | Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. |
| Q38673879 | Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology |
| Q82009235 | Cervical cancer vaccination: the real meaning of cross-protection and its impact on the prevention |
| Q81471680 | Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein |
| Q35890718 | Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope |
| Q34171663 | Characterization of an RNA aptamer against HPV-16 L1 virus-like particles |
| Q36115229 | Characterization of human papillomavirus type 16 pseudovirus containing histones |
| Q35888022 | Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b |
| Q35079915 | Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. |
| Q34032367 | Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine |
| Q40382460 | Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform |
| Q34033805 | Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy |
| Q38832137 | Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells. |
| Q37356046 | Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines |
| Q36240497 | Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV) |
| Q35891225 | Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model |
| Q37226543 | Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops |
| Q36333638 | Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection |
| Q36775528 | Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens |
| Q77793501 | Clinical models of chemoprevention for cervical cancer |
| Q26771981 | Clinical significance of human papillomavirus genotyping |
| Q40533813 | Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells |
| Q95645661 | Collaboration in the War against Viruses: A Multidisciplinary International Effort |
| Q35743769 | Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women |
| Q28246307 | Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines |
| Q37834097 | Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies |
| Q36167475 | Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies |
| Q28654303 | Conserved features in papillomavirus and polyomavirus capsids |
| Q39672622 | Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system |
| Q35595612 | Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein. |
| Q33717736 | Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice |
| Q30051687 | Correlating immunity with protection for HPV infection |
| Q27647874 | Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies |
| Q37135023 | Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. |
| Q35469459 | Current trends in the etiology and diagnosis of HPV-related head and neck cancers |
| Q24616134 | Current understanding of the mechanism of HPV infection |
| Q36097134 | Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles |
| Q38877739 | DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. |
| Q39606580 | DNA-induced structural changes in the papillomavirus capsid |
| Q51663021 | De novo design of an RNA tile that self-assembles into a homo-octameric nanoprism. |
| Q35697573 | Delivering on the promise: HPV vaccines and cervical cancer |
| Q44944872 | Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells |
| Q36857700 | Detection and control of prion diseases in food animals |
| Q43204000 | Detection of antibodies against epidermodysplasia verruciformis-associated canine papillomavirus 3 in sera of dogs from Europe and Africa by enzyme-linked immunosorbent assay |
| Q36522299 | Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus. |
| Q33950282 | Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. |
| Q34089078 | Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report |
| Q34786808 | Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection |
| Q35869579 | Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals |
| Q36269739 | Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies |
| Q34631422 | Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach |
| Q41462631 | Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter |
| Q43493362 | Development of human papillomavirus chimaeric L1/L2 candidate vaccines |
| Q37712837 | Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58 |
| Q37928954 | Development of vaccine delivery vehicles based on lactic acid bacteria |
| Q39021001 | Developments in L2-based human papillomavirus (HPV) vaccines |
| Q38081965 | Developments in virus-like particle-based vaccines for HIV. |
| Q37951525 | Developments in virus-like particle-based vaccines for infectious diseases and cancer |
| Q34227402 | Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses |
| Q75325496 | Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins |
| Q28479209 | Differentiation-dependent interpentameric disulfide bond stabilizes native human papillomavirus type 16 |
| Q74826057 | Direct chemical extraction of a recombinant viral coat protein from Escherichia coli at high cell density |
| Q35928124 | Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens |
| Q45616224 | Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women |
| Q42257816 | Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial |
| Q40608378 | Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles |
| Q44105400 | Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques |
| Q37306139 | Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. |
| Q34074835 | Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. |
| Q36654802 | Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles |
| Q43942291 | Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions |
| Q80821235 | Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant |
| Q90437506 | Epidermal growth factor receptor and Abl2 kinase regulate distinct steps of Human papillomavirus type 16 endocytosis |
| Q47132009 | Escherichia coli-derived virus-like particles in vaccine development |
| Q40929253 | Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors |
| Q37365279 | Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection |
| Q37159499 | Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18. |
| Q36558193 | Evidence for Placental HPV Infection in Both HIV Positive and Negative Women |
| Q35925828 | Evidences of Changes in Surface Electrostatic Charge Distribution during Stabilization of HPV16 Virus-Like Particles |
| Q42785059 | Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. |
| Q47554977 | Explanations for the high potency of HPV prophylactic vaccines |
| Q33283524 | Exploiting the yeast L-A viral capsid for the in vivo assembly of chimeric VLPs as platform in vaccine development and foreign protein expression |
| Q36916029 | Exploring the relation between human papilloma virus and larynx cancer. |
| Q37280045 | Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris |
| Q36426605 | Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles |
| Q36685977 | Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles |
| Q35880936 | Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly |
| Q40097092 | Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana |
| Q91897260 | Felis catus papillomavirus type 2 virus-like particle vaccine is safe and immunogenic but does not reduce FcaPV-2 viral loads in adult cats |
| Q82968713 | Finding a vaccine for human papillomavirus |
| Q38123692 | Fluorosomes: fluorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions |
| Q39603298 | Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins |
| Q42182816 | Functional analysis of HPV-like particle-activated Langerhans cells in vitro. |
| Q38671633 | Functional assessment and structural basis of antibody binding to human papillomavirus capsid |
| Q40344553 | Further evidence that papillomavirus capsids exist in two distinct conformations |
| Q37240280 | Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients |
| Q37640226 | Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs |
| Q39879040 | Generation and neutralization of pseudovirions of human papillomavirus type 33. |
| Q45366363 | Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins |
| Q35114105 | Genital human papillomavirus infection |
| Q34004909 | Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan |
| Q84573785 | HIV-1 derived peptides fused to HBsAg affect its immunogenicity |
| Q35180148 | HPV - immune response to infection and vaccination |
| Q44170300 | HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase |
| Q39320596 | HPV entry into cells |
| Q38971521 | HPV in Head and Neck Cancer-30 Years of History |
| Q35887782 | HPV vaccination for prevention of skin cancer |
| Q34507291 | HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions |
| Q56959368 | HPV vaccines and the prevention of cervical cancer |
| Q81690453 | HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood |
| Q50940137 | HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. |
| Q35498376 | HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model |
| Q39617158 | Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence |
| Q27469539 | Hepatitis C virus structural proteins assemble into viruslike particles in insect cells |
| Q36720700 | Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. |
| Q40639970 | Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines |
| Q33496351 | Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium |
| Q58802346 | Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation |
| Q47136931 | High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16. |
| Q72997924 | Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles |
| Q34119899 | History of vaccination |
| Q38042837 | Host-cell factors involved in papillomavirus entry |
| Q35235035 | How will HPV vaccines affect cervical cancer? |
| Q40451271 | Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia. |
| Q37205058 | Human Papillomavirus Type16- L1 VLP Production in Insect Cells |
| Q37511451 | Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. |
| Q36191708 | Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies |
| Q35748557 | Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. |
| Q33746083 | Human papillomavirus and urological tumours: I. Basic science and role in penile cancer |
| Q37053303 | Human papillomavirus and vaccination in cervical cancer |
| Q38018120 | Human papillomavirus as a target for management, prevention and therapy |
| Q43187047 | Human papillomavirus infection |
| Q24529079 | Human papillomavirus infection requires cell surface heparan sulfate |
| Q36817148 | Human papillomavirus therapeutic vaccines in head and neck tumors |
| Q35069346 | Human papillomavirus therapy for the prevention and treatment of cervical cancer |
| Q33785841 | Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies |
| Q33850734 | Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm |
| Q35852125 | Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments |
| Q35553171 | Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice |
| Q48135326 | Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. |
| Q40423280 | Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate |
| Q92056262 | Human papillomavirus vaccination: Ongoing challenges and future directions |
| Q26853556 | Human papillomavirus vaccination: a case study in translational science |
| Q36690278 | Human papillomavirus vaccines for the treatment of cervical cancer |
| Q37776720 | Human papillomavirus vaccines in plants |
| Q33840918 | Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. |
| Q45865913 | Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo |
| Q36550902 | Human papillomaviruses and cervical cancer |
| Q36162302 | Human papillomaviruses genotyping in plantar warts |
| Q33908917 | Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers |
| Q40131145 | Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles |
| Q39793237 | Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses |
| Q36541188 | Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1 |
| Q36759798 | Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection |
| Q24678291 | Identification of the alpha6 integrin as a candidate receptor for papillomaviruses |
| Q39683911 | Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses |
| Q34019891 | Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus |
| Q36283939 | Immune responses to human papillomavirus |
| Q33853398 | Immunization with a pentameric L1 fusion protein protects against papillomavirus infection |
| Q42273331 | Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model |
| Q35840539 | Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. |
| Q35854601 | Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. |
| Q42278396 | Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras |
| Q40576411 | Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine |
| Q54661607 | Immunohistochemical demonstration of multiple HPV types in laryngeal squamous cell carcinoma. |
| Q73414358 | Immunological analyses of human papillomavirus capsids |
| Q35044376 | Immunoprevention of human papillomavirus-associated malignancies |
| Q27307719 | Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. |
| Q33541956 | Immunotherapeutic strategies for cervical squamous carcinoma |
| Q34033763 | Immunotherapy for cervical cancer: Research status and clinical potential |
| Q36239661 | Immunotherapy for gynaecological malignancies. |
| Q98224681 | Impact of Vaccines; Health, Economic and Social Perspectives |
| Q34125906 | In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection |
| Q84423777 | In planta production of a candidate vaccine against bovine papillomavirus type 1 |
| Q39723134 | In vitro gene transfer using human papillomavirus-like particles |
| Q35867810 | In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype |
| Q34069054 | In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. |
| Q42276716 | In vitro monitoring of the formation of pentamers from the monomer of GST fused HPV 16 L1. |
| Q37685343 | In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression |
| Q38640038 | Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes |
| Q39777974 | Inducible heat shock protein 70 enhances HPV31 viral genome replication and virion production during the differentiation-dependent life cycle in human keratinocytes |
| Q40957603 | Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles |
| Q34725913 | Induction of antibody and interferon-γ production in mice immunized with virus-like particles of swine hepatitis E virus |
| Q37093490 | Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus |
| Q37184404 | Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles |
| Q34933721 | Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus |
| Q46353574 | Induction of immune responses against human papillomaviruses by hypervariable epitope constructs |
| Q38884326 | Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. |
| Q33788701 | Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation |
| Q42193505 | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. |
| Q30376236 | Influenza vaccines based on virus-like particles |
| Q33604135 | Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression |
| Q37909427 | Insect cell technology is a versatile and robust vaccine manufacturing platform |
| Q30764287 | Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection |
| Q36626328 | Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence |
| Q45723919 | Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells |
| Q36637073 | Interaction of papillomaviruses with the cell surface |
| Q24524176 | Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection |
| Q34860943 | Interactions between papillomavirus L1 and L2 capsid proteins |
| Q33782413 | Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. |
| Q36545052 | Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays. |
| Q82456786 | Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels |
| Q34344372 | Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease |
| Q34434903 | Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1 |
| Q37068275 | Involvement of Nucleophosmin (NPM1/B23) in Assembly of Infectious HPV16 Capsids |
| Q40589262 | Kinetics of in vitro adsorption and entry of papillomavirus virions |
| Q39584243 | Kinetics of infected insect cell osmolysis and enhanced protein release using a modified disruption method |
| Q55425847 | L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine. |
| Q33839721 | L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation |
| Q37164879 | L2, the minor capsid protein of papillomavirus |
| Q36311573 | Laboratory and clinical aspects of human papillomavirus testing |
| Q28081156 | Long-term efficacy and safety of human papillomavirus vaccination |
| Q33834872 | Maturation of papillomavirus capsids |
| Q30155145 | Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology |
| Q33856453 | Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions |
| Q92871138 | Mesoscale model of the assembly and cross-linking of HPV virus-like particles |
| Q42182822 | Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro |
| Q26771656 | Molecular pharming - VLPs made in plants |
| Q43636904 | Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. |
| Q37135012 | Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines |
| Q33823755 | Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice |
| Q34075698 | Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination |
| Q38830323 | Multivalent and Multipathogen Viral Vector Vaccines |
| Q34639978 | Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation |
| Q34000082 | Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor |
| Q33822614 | Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes |
| Q33784891 | Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions |
| Q41926483 | Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization |
| Q43605407 | Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region |
| Q36637389 | Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins |
| Q35947703 | Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition |
| Q36933073 | Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia |
| Q37137430 | New Approaches to Immunotherapy for HPV Associated Cancers |
| Q34477924 | New viral vaccines. |
| Q33433442 | Nobel price for vaccination against cervical cancer: current data and guidelines |
| Q35642774 | Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. |
| Q41633745 | Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution |
| Q24294995 | Nuclear import strategies of high risk HPV16 L1 major capsid protein |
| Q40468775 | Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. |
| Q26853380 | Nuns, warts, viruses, and cancer |
| Q54263650 | Opportunities and challenges for human papillomavirus vaccination in cancer. |
| Q33943463 | Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay. |
| Q53383624 | Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. |
| Q43965189 | Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. |
| Q33571959 | Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice |
| Q26801497 | Papillomavirus Infectious Pathways: A Comparison of Systems |
| Q35845291 | Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor |
| Q33785870 | Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines |
| Q38795804 | Papillomavirus assembly: An overview and perspectives |
| Q35831992 | Papillomavirus capsid binding and uptake by cells from different tissues and species. |
| Q33788885 | Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer |
| Q33814170 | Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability |
| Q34699403 | Papillomavirus capsid proteins mutually impact structure |
| Q34178325 | Papillomavirus infection requires gamma secretase |
| Q33614425 | Papillomavirus prophylactic vaccines: established successes, new approaches |
| Q33780651 | Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies |
| Q33847557 | Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses |
| Q35193613 | Papillomavirus vaccines in clinical trials |
| Q45481228 | Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells |
| Q34451862 | Papillomavirus-like particle based vaccines: cervical cancer and beyond |
| Q37219748 | Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice |
| Q37568227 | Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. |
| Q37208883 | Papillomaviruses--to vaccination and beyond |
| Q44182045 | Papillomaviruses: prophylactic vaccine prospects |
| Q40762506 | Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses |
| Q33905022 | Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. |
| Q34011494 | Perspectives for preventive and therapeutic HPV vaccines |
| Q37658876 | Perspectives for the development of human papillomavirus vaccines and immunotherapy |
| Q80206650 | Perspectives of contemporary papillomavirus research |
| Q36827128 | Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine |
| Q38301730 | Physical interaction of human papillomavirus virus-like particles with immune cells |
| Q93002085 | Polymeric micro- and nanoparticles for immune modulation |
| Q43514345 | Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. |
| Q33848323 | Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection |
| Q35228978 | Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women |
| Q82343754 | Prevention is better than cure |
| Q34762053 | Prevention of cancer by prophylactic human papillomavirus vaccines |
| Q34708041 | Prevention of cancer through immunization: Prospects and challenges for the 21st century. |
| Q35620080 | Prevention of cervical cancer through papillomavirus vaccination |
| Q34272029 | Prevention of cervical cancer with vaccines |
| Q37021701 | Prevention, diagnosis, and treatment of cervical cancer |
| Q35037363 | Primary prevention of uterine cervix cancer: focus on vaccine history and current strategy |
| Q37912228 | Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact |
| Q38887093 | Production and evaluation of virus-like particles displaying immunogenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) |
| Q28611356 | Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies |
| Q36555514 | Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells |
| Q40730375 | Production of Influenza Virus HA1 Harboring Native-Like Epitopes by Pichia pastoris |
| Q40047040 | Production of highly immunogenic virus-like particles of bovine papillomavirus type 6 in silkworm pupae |
| Q37014047 | Progress and prospects for L2-based human papillomavirus vaccines |
| Q35919119 | Progress in the development of a cervical cancer vaccine. |
| Q35984558 | Prophylactic HPV vaccines |
| Q36610447 | Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer |
| Q24545449 | Prophylactic human papillomavirus vaccines |
| Q33759930 | Prospects for prevention of HPV-driven oropharynx cancer |
| Q36545925 | Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. |
| Q89969392 | Protection of outbred mice against a vaginal challenge by a Chlamydia trachomatis serovar E recombinant major outer membrane protein vaccine is dependent on phosphate substitution in the adjuvant |
| Q36314993 | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. |
| Q34347179 | Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein |
| Q35151690 | Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity. |
| Q90079811 | Public-private knowledge transfer and access to medicines: a systematic review and qualitative study of perceptions and roles of scientists involved in HPV vaccine research |
| Q80136333 | Quadrivalent human papillomavirus recombinant vaccine |
| Q40610561 | Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants |
| Q39577044 | Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. |
| Q38819439 | Recent advancements in combination subunit vaccine development |
| Q34074998 | Recent advances in diagnosis and therapy of human papillomaviruses |
| Q36647920 | Recent advances in human papillomavirus vaccines |
| Q38075857 | Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases |
| Q35842528 | Recent developments in human papillomavirus vaccines |
| Q38370782 | Recent progress in vaccination against human papillomavirus-mediated cervical cancer |
| Q36366466 | Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma |
| Q30412076 | Recombinant protein vaccines produced in insect cells |
| Q37488845 | Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer |
| Q34244580 | Reducing HPV-associated cancer globally. |
| Q39890236 | Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity |
| Q35866498 | Replication and assembly of human papillomaviruses |
| Q35150925 | Replication and partitioning of papillomavirus genomes |
| Q45753794 | Reversed-phase high-performance liquid chromatography of virus-like particles |
| Q36797004 | Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. |
| Q37860337 | Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile |
| Q33740579 | Roles for human papillomavirus type 16 l1 cysteine residues 161, 229, and 379 in genome encapsidation and capsid stability |
| Q54216752 | Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus. |
| Q40936277 | Roots and perspectives of contemporary papillomavirus research |
| Q56959423 | Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses |
| Q34360259 | Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1. |
| Q37612161 | Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses |
| Q36313476 | Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever |
| Q42245288 | Searching for the initiating site of the major capsid protein to generate virus-like particles for a novel laboratory mouse papillomavirus |
| Q35541886 | Second-generation prophylactic HPV vaccines: successes and challenges |
| Q56959564 | Section Review: Biologicals & Immunologicals: Human papillomavirus infection, genital warts and cervical cancer: prospects for prophylactic and therapeutic vaccines |
| Q26767097 | Self-assembling protein nanoparticles in the design of vaccines |
| Q35228223 | Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. |
| Q38950378 | Self-assembly of nanoparticles into biomimetic capsid-like nanoshells. |
| Q37226380 | Serological relationship between cutaneous human papillomavirus types 5, 8 and 92 |
| Q38874078 | Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs |
| Q34579346 | Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay |
| Q64374754 | Small size, big impact: how studies of small DNA tumour viruses revolutionized biology |
| Q36373404 | Sound efficacy of prophylactic HPV vaccination: Basics and implications |
| Q40396582 | Strategies for mapping and imitating viral B-cell epitopes |
| Q26777382 | Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens |
| Q100519112 | Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs |
| Q41605239 | Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization |
| Q35291103 | Structural studies on antibody-virus complexes |
| Q27625236 | Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 |
| Q41859327 | Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly |
| Q42047559 | Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. |
| Q34071813 | Study of infectious virus production from HPV18/16 capsid chimeras |
| Q91688100 | Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q56355933 | Successful Vaccines |
| Q34408919 | Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype |
| Q42245186 | Surface display of the HPV L1 capsid protein by the autotransporter Shigella IcsA. |
| Q33707499 | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas |
| Q34357038 | Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles |
| Q26824925 | Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy |
| Q101559283 | Targeted next generation sequencing panel for HPV genotyping in cervical cancer |
| Q37033232 | Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles |
| Q27709061 | The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction |
| Q38959835 | The Density Code for the Development of a Vaccine? |
| Q42828087 | The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context |
| Q34181827 | The L1 major capsid protein of human papillomavirus type 11 interacts with Kap beta2 and Kap beta3 nuclear import receptors |
| Q33852592 | The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes |
| Q33673620 | The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system |
| Q21134079 | The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection |
| Q36281141 | The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy |
| Q38603912 | The application of virus-like particles as vaccines and biological vehicles |
| Q50851962 | The beginning of the end: vaccine prevention of HPV-driven cancers. |
| Q28302676 | The current status of therapeutic HPV vaccine |
| Q26861667 | The cytoskeleton in papillomavirus infection |
| Q45197725 | The development of vaccines: how the past led to the future |
| Q36827213 | The evolving field of human papillomavirus receptor research: a review of binding and entry. |
| Q39442569 | The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation |
| Q36679858 | The hallmarks of premalignant conditions: a molecular basis for cancer prevention |
| Q24610004 | The history of tumor virology |
| Q33848178 | The immunology of animal papillomaviruses |
| Q24309388 | The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors |
| Q33781905 | The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains |
| Q37683446 | The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding |
| Q37822798 | The prevention of cervical cancer in Africa |
| Q33936363 | The role of vaccines in the control of STDs: HPV vaccines. |
| Q35541210 | The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine |
| Q47255618 | Therapeutic vaccines for high-risk HPV-associated diseases. |
| Q36622630 | Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids |
| Q24646183 | Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions |
| Q28730718 | Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine |
| Q34353473 | Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. |
| Q43711805 | Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. |
| Q39875296 | Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. |
| Q38041983 | Understanding and learning from the success of prophylactic human papillomavirus vaccines. |
| Q34351909 | Use of the baculovirus expression system for the generation of virus-like particles |
| Q38152475 | VLPs and particle strategies for cancer vaccines |
| Q28280059 | VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus |
| Q38971587 | Vaccination Expectations in HNSCC. |
| Q36066161 | Vaccination strategies for the prevention of cervical cancer |
| Q34054427 | Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection |
| Q40168614 | Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. |
| Q40399200 | Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus |
| Q38087785 | Vaccine design: emerging concepts and renewed optimism |
| Q59350469 | Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen |
| Q35925621 | Vaccines against cervical cancer |
| Q37614961 | Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission |
| Q36601830 | Vaccines for viral and parasitic diseases produced with baculovirus vectors |
| Q37737321 | Vaccines to prevent infections by oncoviruses |
| Q35290961 | Viral assembly using heterologous expression systems and cell extracts |
| Q37792984 | Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design |
| Q38554795 | Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology |
| Q92257210 | Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? |
| Q37608311 | Virus-like particle vaccines and adjuvants: the HPV paradigm |
| Q44084905 | Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development |
| Q37666808 | Virus-like particles as a vaccine delivery system: myths and facts |
| Q35295832 | Virus-like particles as immunogens |
| Q37798008 | Virus-like particles in vaccine development. |
| Q24650772 | Virus-like particles production in green plants |
| Q30817169 | Virus-like particles: a new family of delivery systems |
| Q36837144 | Virus-like particles: flexible platforms for vaccine development |
| Q36602264 | Virus-like particles: passport to immune recognition |
| Q33670688 | Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women |
| Q82970082 | [Anal HPV infections] |
| Q84796169 | [HPV infections of the oral and genital mucosa. Possibilities for primary prevention] |
| Q80275938 | [HPV vaccines. Prophylactic vaccines from virus-like particles] |
| Q80319619 | [Humoral and cellular immune response in HPV vaccination] |
| Q79939143 | [Prophylactic vaccination against human papillomavirus] |
Search more.